MORE RESEARCH. MORE SURVIVORS.
The Lung Cancer Awareness Month Coalition
is a group of leading international research and advocacy organizations that partner each November in an effort to improve outcomes for lung cancer patients across the world. Unlike many other diseases, with lung cancer, there is a shocking lack of knowledge among both patients and physicians about effective risk reduction and treatment options. The Coalition seeks to fill this void, inspiring hope and achieving better results for patients in the process. Most of all, the Coalition strives to debunk the unfair assumptions and stigma associated with lung cancer by better educating the public on the disease and its causes.
MORE FUNDING. NEW RESEARCH.
TARGETED ORAL THERAPY
Epidermal growth factor receptor (EGFR) mutations occur in 10 to 20 percent of NSCLC tumors1, and as high as 60 percent in NSCLC tumors in Asian populations.2 Lung Cancer Survivor, Joan Fong, is alive today because of advances in the identification and treatment of lung cancer, in particular, because of targeted oral therapy that was determined very effective for her particular tumor mutation.
RATES ARE FALLING
Over the last 39 years, the rate of new lung cancer cases has fallen 32% among men while increasing 94% among women. Since the peak rate for men in 1984, the rate of new cases for men has dropped 41%. Since the peak rate of new cases for women in 1998, the rate of new cases for women has fallen 10%.3 Dusty Donaldson, is an 11-year survivor, whose symptoms led her to a diagnosis of stage 1b NSCLC adenocarcinoma. Dusty is alive because the cancer was detected early and eliminated through surgery and chemotherapy. She is still cancer free today.
NEW FDA APPROVAL
The FDA approved the first personalized medicine for certain epidermal growth factor receptor (EGFR) mutation-positive metastatic NSCLC in the USA in May of 2013. The drug is called erlotinib, and it was approved for initial (first-line) treatment of people with NSCLC whose tumors have been identified to have certain EGFR mutations by an FDA approved test. A 39 year old lung cancer survivor and mother of four, Jill Feldman, was diagnosed with the EGFR mutation and began receiving personalized treatment.